|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study显示文摘 | Giancarlo Agnelli Gualberto Gussoni Carlo Bianchini Melina Verso Mario Mandalà Luigi Cavanna Sandro Barni Roberto Labianca Franco Buzzi Giovanni Scambia Rodolfo Passalacqua Sergio Ricci Giampietro Gasparini Vito Lorusso Erminio Bonizzoni Maurizio Tonato | 2009 | Lancet Oncology2009，，10： | 1 |
| 2 | Colon cancer显示文摘 | Roberto Labianca Giordano D. Beretta Basem Kildani Laura Milesi Federica Merlin Stefania Mosconi M. Adelaide Pessi Tiziana Prochilo Antonello Quadri Gemma Gatta Filippo de Braud Jacques Wils | 2010 | Critical Reviews in Oncology and Hematology2010，，2： | 1 |
| 3 | Raltitrexed (Tomudex ? ) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)显示文摘 | Ivan Popov Alfredo Carrato Alberto Sobrero Mark Vincent David Kerr Roberto Labianca Angelo Raffaele Bianco Mostafa El-Serafi Laurent Bedenne Bernard Paillot Enrico Mini Evaristo Sanches John Welch Laurence Collette Michel Praet Jacques Wils | 2008 | European Journal of Cancer2008，，15： | 1 |
| 4 | Chemotherapy-associated thromboembolic risk in cancer outpatients and effect ofnadroparin thromboprophylaxis: Results of a retrospective analysis of thePROTECHT study显示文摘 | Sandro Barni Roberto Labianca Giancarlo Agnelli | 2011 | J Transl Med2011，9，： | 1 |
| 5 | Cholangiocarcinoma显示文摘 | Stefania Mosconi Giordano D Beretta Roberto Labianca | 2009 | Critical Reviews in Oncology/Hematology2009，69，25： | 1 |
| 6 | Gastric cancer显示文摘 | Vincenzo Cata|ano Roberto Labianca Giordano D Be- retta | 2009 | Critical Reviews in Oncol- ogy/Hematology2009，71，： | 1 |
| 7 | Gastric cancer显示文摘 | Vincenzozo Catalano Roberto Labianca Giordano D | | 0，，01： | 1 |
| 8 | Activity and safety of pegylated liposomal doxorubicin,5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma:A phase Ⅱ study显示文摘AIM: To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase Ⅱ study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA). METHODS: Thirty-one patients with hystologically- confirmed, inoperable HCC, received combination chemotherapy with PLD 25 mg/mq on d 1, 5FU 1200 mg/mq in 48 h continuous infusion, and oral FA 30 mg on d 1 and 2 every 3 wk until disease progression or intolerable toxicity. RESULTS: The median age was 65 years (range 41-82) and 28 patients were hepatitis C virus seropositive (90%). The majority of patients were Child-Pugh Class B (55%). Two patients showed a partial response (PR), and 16 had stable disease (SD). With a median follow-up of 14 mo, the median time to progression of all evaluable patients was 4 mo (95% CI 1.7-7). Median overall survival was 9 mo (95% CI 3-24 mo). After 1 year, 9 of 18 PR/SD patients were alive. Chemotherapy was well tolerated. CONCLUSION: PLD/FU/FA combination seems capable of achieving durable stabilization of HCC. The manageable toxicity supports a role for combination with other anticancer agents. | Giuseppe Di Lorenzo Antonio Rea Chiara Carlomagno Stefano Pepe Giovannella Palmieri Roberto Labianca Antonio Chirianni Alfonso De Stefano Vincenzo Esposito Sabino De Placido Vincenzo Montesarchio | 2007 | World Journal of Gastroenterology2007，13，48： | 1 |
| 9 | A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score显示文摘 | Melina Verso Giancarlo Agnelli Sandro Barni Giampietro Gasparini Roberto LaBianca | 2012 | Internal and Emergency Medicine2012，，： | 1 |
| 10 | Edmonton symptom assessment scale: Italian validation in two palliative care settings显示文摘 | Cecilia Moro Cinzia Brunelli Guido Miccinesi Mauro Fallai Piero Morino Massimo Piazza Roberto Labianca Carla Ripamonti | 2006 | Supportive Care in Cancer2006，，1： | 1 |
| 11 | Gastric Cancer显示文摘 | Vincenzo Catalano Roberto Labianca Giordano Bet'eRa | 2005 | Oncology/Hematology2005，54，5： | 1 |
| 12 | Gastric cancer显示文摘 | Vincenzo Catalano Roberto Labianca Giordano D. Beretta Gemma Gatta Filippo de Braud Eric Van Cutsem | 2009 | Critical Reviews in Oncology and Hematology2009，，2： | 1 |
| 13 | Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial显示文摘 | Stefano Cascinu Rossana Berardi Roberto Labianca Salvatore Siena Alfredo Falcone Enrico Aitini Sandro Barni Francesco Di Costanzo Elisa Dapretto Giuseppe Tonini Chiara Pierantoni Salvatore Artale Silvia Rota Irene Floriani Mario Scartozzi Alberto Zaniboni | 2008 | Lancet Oncology2008，，1： | 1 |
| 14 | FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study显示文摘 | Alberto Zaniboni Enrico Aitini Sandro Barni Daris Ferrari Stefano Cascinu Vincenzo Catalano Giuseppe Valmadre Domenica Ferrara Enzo Veltri Claudio Codignola Roberto Labianca | 2012 | Cancer Chemotherapy and Pharmacology2012，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员